Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether weight-based or fixed starting doses result
in comparable hemoglobin increases and treatment effects in patients with heart failure and
anemia.